{"commentary":{"count":111,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":61,"podcast":27,"x_thread":21,"x_video":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04603495\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"MANIFEST-2","nct_id":"NCT04603495","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=manifest-2-nct04603495. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"MANIFEST-2","arms":[{"description":"Pelabresib monohydrate tablets + ruxolitinib phosphate tablets","label":"Pelabresib + ruxolitinib","type":"EXPERIMENTAL"},{"description":"Matching placebo tablets + ruxolitinib phosphate tablets","label":"Placebo + ruxolitinib","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-06-30","type":"ESTIMATED"},"conditions":["Myelofibrosis","Primary Myelofibrosis","Post-polycythemia Vera Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis"],"enrollment":{"count":430,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pelabresib","type":"DRUG"},{"name":"Ruxolitinib","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"last_update":"2026-07-17","lead_sponsor":"Novartis Pharmaceuticals","official_title":"A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2023-08-23","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants With Splenic Response by Central Radiology Reads at Week 24","timeFrame":"Week 24"}],"references":[{"citation":"Harrison CN, Gupta VK, Gerds AT, Rampal R, Verstovsek S, Talpaz M, Kiladjian JJ, Mesa R, Kuykendall AT, Vannucchi AM, Palandri F, Grosicki S, Devos T, Jourdan E, Wondergem MJ, Al-Ali HK, Buxhofer-Ausch V, Alvarez-Larran A, Patriarca A, Kremyanskaya M, Mead AJ, Akhani S, Sheikine Y, Colak G, Mascarenhas J. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. Future Oncol. 2022 Sep;18(27):2987-2997. doi: 10.2217/fon-2022-0484. Epub 2022 Aug 11.","pmid":"35950489","type":"RESULT"},{"citation":"Rampal RK, Grosicki S, Chraniuk D, Abruzzese E, Bose P, Gerds AT, Vannucchi AM, Palandri F, Lee SE, Gupta V, Lucchesi A, Oh ST, Kuykendall AT, Patriarca A, Alvarez-Larran A, Mesa R, Kiladjian JJ, Talpaz M, Scandura JM, Lavie D, Harris M, Kays SK, Li Q, Boxhammer R, Brown B, Jegg AM, Harrison CN, Mascarenhas J. Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial. Nat Med. 2025 May;31(5):1531-1538. doi: 10.1038/s41591-025-03572-3. Epub 2025 Mar 10.","pmid":"40065169","type":"RESULT"}],"start_date":{"date":"2021-04-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)","url":"https://clinicaltrials.gov/study/NCT04603495"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/manifest-2-nct04603495"}